In collaboration with multiple pharmaceutical companies as well as investigators at leading academic centers, Brooklyn ImmunoTherapeutics is exploring the potential of IRX-2 in other oncology indications.
We are conducting clinical trials in combination with other anti-cancer agents such as checkpoint inhibitors. Immune checkpoint inhibitors are a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immune-checkpoint-inhibitor
By combining IRX-2 with anticancer therapies including checkpoint inhibitors, we will be able to determine if a potentially larger number of patients can benefit than if treated with either therapy alone. In clinical trials to date, IRX-2 has also been well-tolerated by patients which makes it potentially better able to combine with other anti-cancer agents.
The following charts show on-going trials of IRX-2 in other cancer indications as well as proposed clinical trials.